In the past week, CNSP stock has gone up by 17.74%, with a monthly decline of -39.88% and a quarterly plunge of -42.86%. The volatility ratio for the week is 11.28%, and the volatility levels for the last 30 days are 19.07% for Cns Pharmaceuticals Inc The simple moving average for the past 20 days is -1.97% for CNSP’s stock, with a -91.68% simple moving average for the past 200 days.
Is It Worth Investing in Cns Pharmaceuticals Inc (NASDAQ: CNSP) Right Now?
Company’s 36-month beta value is 0.76.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CNSP is 2.72M, and currently, short sellers hold a 9.87% ratio of that floaft. The average trading volume of CNSP on March 17, 2025 was 629.98K shares.
CNSP) stock’s latest price update
Cns Pharmaceuticals Inc (NASDAQ: CNSP)’s stock price has soared by 15.13 in relation to previous closing price of 2.71. Nevertheless, the company has seen a gain of 17.74% in its stock price over the last five trading days. accessnewswire.com reported 2025-02-26 that Cash on hand provides over one year of runway to fund expected operations HOUSTON, TX / ACCESS Newswire / February 26, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today provided an update on its current cash position and discussed the completion of its recent initiative to maintain its listing on the NASDAQ Capital Market (“NASDAQ”). “As we kick off 2025, the Company has never been fundamentally stronger.
Analysts’ Opinion of CNSP
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see CNSP reach a price target of $11. The rating they have provided for CNSP stocks is “Buy” according to the report published on August 24th, 2020.
CNSP Trading at -29.88% from the 50-Day Moving Average
After a stumble in the market that brought CNSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.72% of loss for the given period.
Volatility was left at 19.07%, however, over the last 30 days, the volatility rate increased by 11.28%, as shares sank -42.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -44.78% lower at present.
During the last 5 trading sessions, CNSP rose by +17.74%, which changed the moving average for the period of 200-days by -99.40% in comparison to the 20-day moving average, which settled at $3.18. In addition, Cns Pharmaceuticals Inc saw -48.17% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CNSP
Current profitability levels for the company are sitting at:
- -2684.89 for the present operating margin
- 0.6 for the gross margin
The net margin for Cns Pharmaceuticals Inc stands at -2681.03. The total capital return value is set at -5.1. Equity return is now at value -2116.75, with -350.34 for asset returns.
Based on Cns Pharmaceuticals Inc (CNSP), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -454.64. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1052.64.
Currently, EBITDA for the company is -18.86 million with net debt to EBITDA at 0.41. When we switch over and look at the enterprise to sales, we see a ratio of 252.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.81.
Conclusion
In a nutshell, Cns Pharmaceuticals Inc (CNSP) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
